By Gareth Presch, Founder & CEO of the World Health Innovation Summit (WHIS)
The data is clear: true economic competitiveness isn’t just about cutting red tape or tweaking fiscal policy—it is driven by strategic, productive investment in human capital. At the World Health Innovation Summit (WHIS), we have always operated on the core belief that human potential and economic prosperity are deeply intertwined.
To build long-term wealth, nations and leaders must invest heavily in our most vital asset: our health.
“Technology alone does not transform health. People do, when they are equipped with the right tools, supported by trusted frameworks, and empowered within their communities. Today, 97% of global healthcare spending goes toward treating illness rather than preventing it. Shifting our focus to prevention isn’t just a clinical priority, it’s the single smartest business decision a nation can make.” — Gareth Presch
📉 The Global Imbalance: Where Investment Is Heading
The latest report from the McKinsey Global Institute, Catalyzing Competitiveness: Where Investment Happens and Why, sheds light on a stark global divergence in how regions fund future growth.
- Surging Industrial Policy: Industrial policy and state aid are rising globally, but the playing field is drastically uneven.
- The Subsidies Gap: On average, firms in China receive roughly 2.5% of annual revenue in subsidies, compared to just 1% in North America and less than 0.5% in Europe.
- Scale Differences: In strategic manufacturing and technology sectors, China’s average revenue support for strategic firms is over 10x higher than the EU’s and 8x higher than the USA’s. We cannot expect to rebuild true economic competitiveness if we ignore how production, labor productivity, and human capital intersect.
🩺 The Hidden Bottleneck in Healthcare & Life Sciences
The McKinsey report highlights that while the global pharmaceutical and biotechnology sectors are expanding faster than overall global GDP, legacy regions face severe structural headwinds:
- Slower Timelines: Bringing a new biopharmaceutical drug through R&D in legacy markets costs global companies roughly 2.7 times more than fast-moving competitors in China.
- Commercialization Delays: Much of this cost difference stems from an average 2.5-year delay in time to market.
- Impact on Care: These delays compress commercialization windows, driving up baseline costs and stalling the delivery of transformative therapies to patients who need them most.
🚀 The WHIS Vision: Shifting from Sick-Care to Prevention
At WHIS, we are addressing economic competitiveness at its root cause by driving a paradigm shift toward preventive, community-led care.
Traditional “Sick-Care” ApproachPrevention-First Economic PlayFocuses 97% of resources on reactive treatmentDirects capital toward early intervention and health optimizationHigh structural costs and long development timelinesAutomated healthcare data systems and streamlined deliverySqueezes labor productivity through preventable chronic illnessSupercharges worker productivity and extends workforce longevityTreats health spending as a fiscal burdenTreats health spending as an economic value driver
By deploying advanced technologies, automating healthcare data systems, and streamlining care delivery processes, we eliminate inefficiencies and lower structural overhead.
When we protect and optimize human health, we directly supercharge worker productivity, foster sustainable innovation, and build a resilient society capable of long-term economic growth.
The Takeaway
True national resilience isn’t achieved solely through securing raw materials or supply chains—it is built by safeguarding the health of our people. Because when Health equals Wealth, investing in prevention isn’t just good medicine—it’s the ultimate economic strategy.
To explore the detailed data on global investment trajectories, read the full insights on the McKinsey Global Institute report here**.